Principal Investigators: Pam Sharma, MD, PhD; Neal Rosen, MD, PhD; Jim Allison, PhD
Memorial Sloan-Kettering Cancer Center
The University of Texas MD Anderson Cancer Center

Immunotherapy of Prostate Cancer

• Demonstrated that Ipilimumab (Ipi) treatment, up for FDA approval (Q4 2010) for melanoma, causes T cells (a type of white blood cell) to produce a molecule, ICOS, on the cell surface in prostate cancer and melanoma patients.
• Blood tests of Ipi-treated patients indicated that those with high levels of ICOS on their T cells post-treatment survive longer. These findings will be validated in a Phase III trial.
• Three Phase III trials testing Ipilimumab in metastatic prostate cancer patients are open and accruing.